Literature DB >> 11761439

Purified hybrid cells from dendritic cell and tumor cell fusions are superior activators of antitumor immunity.

J Li1, L M Holmes, K J Franek, K E Burgin, T E Wagner, Y Wei.   

Abstract

The use of fusions between dendritic cells (DCs) and tumor cells as vaccines has been proved very effective in stimulating antitumor immune responses, both in animal studies and in early human clinical trials. Because of the difficulty of purifying the hybrid cells from the fusion, fusion mixtures were used in these studies. Recently, we developed a technique using fluorescent-dye staining and fluorescence-activated cell sorting that enabled the hybrid cells to be instantly purified from the fusion mixture. In the present study, the hybrid cells were purified from a fusion between mouse DCs and B16F0 melanoma tumor cells using the new technique. The purified cells, named instant dendritomas (IDs) were then compared with fusion mixtures in stimulating antitumor immune responses. The results from cytotoxicity assays, interferon-gamma production and in vivo lung tumor metastasis demonstrated that IDs are more effective than fusion mixture in stimulating antitumor immunity. Meanwhile, there was no significant difference in the antitumor immunities activated by IDs from allogenic fusion or IDs from syngenic fusion.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11761439     DOI: 10.1007/s002620100218

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  12 in total

Review 1.  Cancer vaccine by fusions of dendritic and cancer cells.

Authors:  Shigeo Koido; Eiichi Hara; Sadamu Homma; Yoshihisa Namiki; Toshifumi Ohkusa; Jianlin Gong; Hisao Tajiri
Journal:  Clin Dev Immunol       Date:  2010-02-18

2.  The immunotherapeutic effect of dendritic cells vaccine modified with interleukin-18 gene and tumor cell lysate on mice with pancreatic carcinoma.

Authors:  Zhao-Hui Tang; Wen-Hong Qiu; Gao-Song Wu; Xiang-Ping Yang; Sheng-Quan Zou; Fa-Zu Qiu
Journal:  World J Gastroenterol       Date:  2002-10       Impact factor: 5.742

3.  Generation of highly pure fusions of colorectal carcinoma and antigen-presenting cells.

Authors:  Ulrike Klier; Claudia Maletzki; Ernst Klar; Michael Linnebacher
Journal:  Langenbecks Arch Surg       Date:  2010-03-23       Impact factor: 3.445

4.  Preparation of a heat-shock protein 70-based vaccine from DC-tumor fusion cells.

Authors:  Desheng Weng; Stuart K Calderwood; Jianlin Gong
Journal:  Methods Mol Biol       Date:  2011

5.  Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules.

Authors:  Maria R Parkhurst; Cormac DePan; John P Riley; Steven A Rosenberg; Suyu Shu
Journal:  J Immunol       Date:  2003-05-15       Impact factor: 5.422

6.  Antigen-specific polyclonal cytotoxic T lymphocytes induced by fusions of dendritic cells and tumor cells.

Authors:  Shigeo Koido; Sadamu Homma; Eiichi Hara; Yoshihisa Namiki; Toshifumi Ohkusa; Jianlin Gong; Hisao Tajiri
Journal:  J Biomed Biotechnol       Date:  2010-04-07

Review 7.  Immunologic monitoring of cellular responses by dendritic/tumor cell fusion vaccines.

Authors:  Shigeo Koido; Sadamu Homma; Akitaka Takahara; Yoshihisa Namiki; Hideo Komita; Eijiro Nagasaki; Masaki Ito; Keisuke Nagatsuma; Kan Uchiyama; Kenichi Satoh; Toshifumi Ohkusa; Jianlin Gong; Hisao Tajiri
Journal:  J Biomed Biotechnol       Date:  2011-04-26

Review 8.  Regulation of tumor immunity by tumor/dendritic cell fusions.

Authors:  Shigeo Koido; Sadamu Homma; Eiichi Hara; Yoshihisa Namiki; Akitaka Takahara; Hideo Komita; Eijiro Nagasaki; Masaki Ito; Toshifumi Ohkusa; Jianlin Gong; Hisao Tajiri
Journal:  Clin Dev Immunol       Date:  2010-10-26

9.  Cell fusion in tumor progression: the isolation of cell fusion products by physical methods.

Authors:  Filippo Pedrazzoli; Iraklis Chrysantzas; Luca Dezzani; Vittorio Rosti; Massimo Vincitorio; Giammaria Sitar
Journal:  Cancer Cell Int       Date:  2011-09-20       Impact factor: 5.722

Review 10.  Novel dendritic cell-based vaccination in late stage melanoma.

Authors:  Erika J Schneble; Xianzhong Yu; T E Wagner; George E Peoples
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.